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Abstract  
Several reports indicate that melatonin is involved in the regulation of bone metabolism. To 
examine the direct effect of melatonin on osteoclasts and osteoblasts, we developed an in 
vitro assay using fish scales that contain osteoclasts, osteoblasts, and bone matrix, all of 
which are similar to those found in mammalian membrane bone. Using the assay, we 
demonstrated that melatonin suppressed osteoclastic and osteoblastic activities. These 
findings are in agreement with the reports from in vivo studies in mice and rats. In an attempt 
to develop molecules that increase bone mass, novel bromomelatonin derivatives were 
synthesized, and the effects of these chemicals on osteoclasts and osteoblasts using the scale 
assay were examined. As a result, novel bromomelatonin derivatives with the ability to 
possibly increase bone formation were identified. In scale osteoclasts, particularly, 
1-benzyl-2,4,6-tribromomelatonin had a more potent activity than melatonin. In reference to 
osteoblasts, this agent (10-9 to 10-6 M) significantly activated osteoblasts. The effect of 
1-benzyl-2,4,6-tribromomelatonin on bone formation was confirmed in ovariectomized rats. 
Thus, the oral administration of 1-benzyl-2,4,6-tribromomelatonin augmented the total bone 
mineral density of the femoral metaphysis of ovariectomized rats. The stress-strain index of 
the diaphysis in 1-benzyl-2,4,6-tribromomelatonin-treated rats significantly increased in 
comparison with that in ovariectomized rats. In rats fed a low-calcium diet, the total bone 
mineral density of the femoral metaphysis significantly increased following the oral 
administration of 1-benzyl-2,4,6-tribromomelatonin. These studies identified a melatonin 
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Introduction 
Melatonin, N-acetyl-5-methoxytryptamine, is the principal secretory product of the vertebrate 
pineal gland and is synthesized almost exclusively during darkness; as a result, blood levels 
exhibit a conspicuous circadian rhythm [1, 2]. In mammals, including man, nighttime 
melatonin levels progressively drop throughout life [3, 4]; therefore, nocturnal melatonin 
levels in older individuals are much lower than in younger ones [5].  
Melatonin prevents phototherapy-induced hypocalcemia in newborn rats [6]. Thus, the 
regulation of calcium homeostasis and bone metabolism by melatonin is suggested. 
Subsequently, the direct effects of melatonin on osteoclasts and osteoblasts were examined 
[7] using an in vitro assay system [8] with fish scales containing osteoclasts, osteoblasts, and 
bone matrix. Using this system, evidence was provided that melatonin suppressed osteoclastic 
and osteoblastic activities [7]. Thereafter, we synthesized novel melatonin derivatives and 
demonstrated that some of these agents inhibited osteoclastic activity but increased 
osteoblastic activity in the scale assay system [9]. Preliminary studies also indicated that, in 
ovariectomized rats, the melatonin derivative significantly increased the stress-strain index of 
the diaphysis and significantly augmented the total bone mineral density in the femoral 
metaphysis in rats fed a low-calcium diet.  
Novel indole derivatives assayed using the in vitro scale assay system indicate that a 
melatonin derivative may have potential benefits for the treatment of bone diseases, such as 
osteoporosis. In the present review, we discuss the implications of melatonin and melatonin 
derivatives for bone disease therapy. 
 
Melatonin, calcium metabolism and spinal deformities 
Csaba and collaborators [10-12] were the first to report a relationship between the pineal and 
calcium-regulating endocrine glands, such as the parathyroid gland and parafollicular cells of 
the thyroid gland. This was shown in experiments using pinealectomized rats. In the hamster, 
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the ultrastructure of the parathyroid gland was also affected by melatonin treatment [13, 14]. 
As both melatonin and pineal extract reduced the serum calcium levels in rats [15], it is 
surmised that melatonin may be a calcemic hormone.  
Spinal malformations have been reported in chickens [16-20], rats [21], and fish [22] after 
surgical ablation of the pineal gland. The experimental scoliosis observed in pinealectomized 
chickens was similar to that in human idiopathic scoliosis. However, the role of melatonin in 
the development of spinal deformities in pinealectomized chickens is less clear. Machida et al. 
[16] reported that pinealectomy in young chickens followed by transplantation of the pineal 
gland led to recovery of the serum melatonin levels and a significant reduction in pre-existing 
spinal deformities. Conversely, Turgut et al. [23] claimed that pineal transplantation following 
pinealectomy in young chickens had no significant effect on the development of scoliosis, 
even though serum melatonin returned to their normal levels. It is possible that the effects of 
pinealectomy on the spinal column may be an indirect effect related to the pathophysiological 
consequences of disrupted biorhythms, rather than to a direct effect of melatonin [20].  
 
Melatonin and bone metabolism in osteoblast cell lines 
High concentrations of melatonin and the activities of the enzymes (arylalkylamine   
N-acetyltransferase and hydroxyindole-O-methoxyltransferase) which synthesize melatonin 
from serotonin have been identified in bone marrow [24, 25]. To investigate the potential 
pineal origin of bone marrow melatonin, long-term (8 months) pinealectomized rats were 
used. The authors found that the bone marrow in the pinealectomized rats still exhibited high 
levels of melatonin even though the pineal gland had been removed 8 months earlier [24]. 
These results suggest that the melatonin in bone metabolism is not of pineal origin.  
Roth et al. [26] examined the direct effect of melatonin on osteoblasts using two cell lines: 
MC3T3-E1 pre-osteoblasts and rat osteoblast-like osteosarcoma 17/2.8 cells. Bone 
sialoprotein is an acidic, tyrosine-sulfated, extracellular bone matrix protein that is expressed 
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during osteoblastic cell differentiation and is required for mineralization. Melatonin increased 
the expression of bone sialoprotein as well as several other essential bone marker proteins, 
including alkaline phosphatase (ALP) and osteocalcin. In addition, melatonin stimulated both 
osteoblast differentiation and mineralization [26].  
In another study, melatonin acted directly on human bone cells (HOB-M) and an 
osteoblast cell line (SV-HFO) and dose-dependently increased the proliferation in both cell 
types, with a maximal effect being achieved at a concentration of 50 μM [27]. Type 1 
collagen synthesis also was elevated in both cell types [27]. In a more recent study, reverse 
transcription-polymerase chain reaction and Western blot analysis showed that human 
osteoblasts express the melatonin Ia receptor and that its expression levels decrease gradually 
with the age of the host [28]. Collectively, these findings using osteoblast cell lines indicate 
that melatonin has a promotional action on osteoblasts. 
 
Melatonin therapy for bone diseases such as osteoporosis  
Sack et al. [4] reported that melatonin secretion decreased sharply during menopause. This 
reduction may contribute to post-menopausal osteoporosis. In the ovariectomized rat model of 
post-menopausal osteoporosis, the serum melatonin levels negatively correlated with the 
biochemical markers of bone resorption (cross-linked carboxyterminal telopeptide of type I 
collagen in serum, hydroxyproline in urine, and total calcium in urine) [29]. A negative 
correlation between the salivary melatonin levels and the biochemical markers of bone 
resorption was also found in post-menopausal obese women [30]. 
Ladizesky et al. [31] tested the effect of melatonin in ovariectomized rats. Urinary 
deoxypyridinoline (bone resorption marker) increased significantly after ovariectomy by 51% 
(30 days after surgery) and by 47% (60 days after surgery). Following melatonin 
administration (25 μg/ml water), the increase in urinary deoxypyridinoline found at 30 days 
after ovariectomy was not observed. However, the bone mineral density and content as well 
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as bone area did not change at 60 days after surgery. To augment the bone area and bone 
mineral content in rats that had been ovariectomized, melatonin required small amounts of 
estrogen (10 μg/kg BW, 5 days/week) [32]. In intact mice, pharmacological doses (5 or 50 
mg/kg BW/day) of melatonin elevated the bone mineral density [33]. This treatment 
significantly reduced the bone resorption parameters, including the osteoclastic surface and 
osteoclastic number, but did not increase the histomorphometric bone formation parameters 
(bone formation rate, mineral apposition rate, and osteoid volume) [33]. The skeletal effects 
of melatonin are, presumably, a result of the inhibition of osteoclast activity. In addition, a 
pharmacological dose (10 or 30 mg/kg BW/day) of melatonin elevated the trabecular 
thickness and trabecular area of the vertebra and femur and the cortical thickness of the femur 
in ovariectomized rats [34]. Based on currently available data, physiological doses of 
melatonin supplementation with estrogen or pharmacological doses of melatonin are required 
to increase the bone mineral content or bone mineral density, respectively, in the 
ovariectomized rat model of post-menopausal osteoporosis.   
 
A novel assay system using fish scales 
The teleost scale is a calcified tissue (Fig.1A) that contains osteoclasts (Fig.1B) and 
osteoblasts (Fig.1C) [8, 35-38]; these cells are similar to those found in avian and mammalian 
membrane bones. In the scale as well as in mammalian bone, the bone matrix includes type I 
collagen [39], bone γ-carboxyglutamic acid protein [40], and osteonectin [41]. Hydroxyapatite 
also exists in the scale [42]. In addition, multi-nucleated osteoclasts (the active type of 
osteoclasts) have been detected in the goldfish scale using in situ hybridization of cathepsin K 
[43]. The scales of some teleosts contain as much as 20% of the total body calcium and are, 
thus, a better potential internal calcium reservoir than vertebral bone during periods of 
increased calcium demand, such as sexual maturation and starvation [35-37, 44, 45]. Teleost 
scales are a simple and suitable model for bone. Considering these facts, we developed an in 
 7  
vitro assay system using the teleost scale to study bone metabolism [7, 8]. In this system, 
tartrate-resistant acid phosphatase (TRAP) and ALP were used as respective markers of 
osteoclasts and osteoblasts. It is known that these enzymes can be utilized as markers for 
these cells in mammals [46, 47]. In the fish scale, TRAP (Fig.1B) and ALP (Fig.1C) are also 
detected in these cells. The respective enzyme activity from a single scale can be detected 
after directly incubating the scale with the appropriate substrate. From one fish, roughly 100 
scales having similar cell activity can be obtained. 
Using this in vitro assay system, we found that melatonin suppressed both osteoclastic and 
osteoblastic activities [7]. This was the first report related to the function of melatonin in 
osteoclasts and the inhibitory effect of melatonin in osteoblasts in any vertebrate species. 
Melatonin also suppressed osteoblastic activity in an in vivo experiment using ovariectomized 
rats [32] as well as in an in vitro co-culture scale system of osteoclasts and osteoblasts. 
Furthermore, high endogenous levels of melatonin correlated with low levels of bone-forming 
markers (i.e., ALP and carboxyterminal propeptide of type I procollagen) in male rats [48]. 
Thus, a co-culture of osteoclasts and osteoblasts should be used to evaluate the effect of 
melatonin on bone metabolism. An interaction between osteoclasts and osteoblasts was also 
recently noted in mammals, and both actions must be considered when examining bone 
metabolism [49, 50]. The receptor activator of NF-κB (RANK) and the receptor activator of 
the NF-κB ligand (RANKL) have been identified in osteoclasts and osteoblasts, respectively 
[51]. Multi-nucleated osteoclasts (an active type of osteoclasts) are activated by the binding of 
RANKL to RANK [51]. A report showing that melatonin reduces the mRNA levels for 
RANKL in the osteoblast cell line [33] is consistent with our hypothesis that melatonin 
inhibits osteoblastic activity. 
 
Bromomelatonin derivatives: Effects on osteoclastic and osteoblastic activities  
The structures of the derivatives examined are illustrated in Figure 2. The details of the 
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studies are described in Suzuki et al. [9]. Melatonin (10-8, 10-6, and 10-4 M) suppressed the 
osteoclastic activity. For 2-bromomelatonin and 2,4,6,8-tetrabromomelatonin, the inhibitory 
action was less than that of melatonin, at least under the in vitro conditions using fish scales. 
The strength of the suppression of osteoclastic activity by tribromomelatonin derivatives 
(2,4,6-tribromomelatonin, 1-allyl-2,4,6-tribromomelatonin, 
1-propargyl-2,4,6-tribromomelatonin, and 1-benzyl-2,4,6-tribromomelatonin) was similar to 
that of melatonin. While melatonin inhibited the osteoblastic activity, all bromomelatonin 
derivatives shown in Figure 2 had a promotional action of osteoblasts. In particular, 
1-benzyl-2,4,6-tribromomelatonin (benzyl-tribromomelatonin) possessed the strongest 
stimulatory activity for osteoblasts. We subsequently analyzed the detailed actions of this 
derivative on scale osteoclasts and osteoblasts and compared them with those of melatonin.  
Benzyl-tribromomelatonin had a stronger activity in osteoclasts than did melatonin. This 
inhibitory action of the derivative remains effective at 10-10 M after 6 h of incubation. In 
addition, benzyl-tribromomelatonin activated osteoblasts (10-9 to 10-6 M) after 6 h of 
incubation, while melatonin (10-8 to 10-6 M) suppressed osteoblastic activity. The action of 
these agents on osteoclasts and osteoblasts after 18 h incubation was similar to that at 6 h of 
incubation. In addition, estrogen receptor mRNA expression (an osteoblastic marker) was 
increased in benzyl-tribromomelatonin (10-7 M)-treated scales. A different receptor for 
bromomelatonin may exist in osteoblasts. Bromomelatonin derivatives theoretically bind to 
this receptor and activate osteoblastic activity. Certainly, different actions of melatonin and 
melatonin-related substances have been reported in a variety of studies [52-54]. Plans are 
underway to examine the characterization of binding for melatonin and bromomelatonin 
derivatives using both goldfish scale and mammalian osteoblastic cell lines.  
 
Effect of benzyl-tribromomelatonin on bone tissues in ovariectomized rats and 
low-calcium diet rats 
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We have confirmed the effect of benzyl-tribromomelatonin on bone using the two common 
animal models of bone diseases (ovariectomized rats and low-calcium diet rats).  
Oral administration of benzyl-tribromomelatonin (0.6 mg/ animal/ day) led to increase the 
total bone mineral density of the femoral metaphysis in ovariectomized rats (Table 1). Using 
the stress-strain index of the diaphysis, a significant difference was recorded between the 
ovariectomized animals that received 1-benzyl-2,4,6-tribromomelatonin and those that did not 
(Table 1). In addition, compression analysis of the femoral metaphysis indicated that the 
values of stiffness, bone fracture force, fracture energy, and maximum load tended to increase 
after 1-benzyl-2,4,6-tribromomelatonin treatment.  
In rats fed a low-calcium diet, total bone mineral density in the femoral metaphysis 
significantly increased due to oral administration of 1-benzyl-2,4,6-tribromomelatonin (0.3 or 
3 mg/ animal/ day) (Table 2). In the compression test, the values of stiffness, fracture energy, 
and maximum load in 1-benzyl-2,4,6-tribromomelatonin-treated rats were higher than those 
for the control animals.  
Thus, the results using the scale assay system were reproduced in mammalian models of 
bone diseases. Additional studies will be required to examine the detailed mechanisms of the 
bromomelatonin derivatives in rat models of bone diseases. In addition, the actions of some 
bromomelatonin derivatives seem to resemble, in some respects, those of the 
osteoporosis-fighting drugs, i.e., bisphosphonates. Given that these latter drugs occasionally 
cause osteonecrosis of the jaw, this may be a potential side effect of melatonin derivatives to 
which attention must be given [55].  
 
Conclusion 
Melatonin directly influences bone metabolism. Judging from in vivo studies, the skeletal 
effects of melatonin probably are a result of its inhibition of osteoclasts. In osteoblasts, a 
suppressive action of melatonin has been detected in vivo, while a promotional effect was 
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recorded in vitro. 
In ovariectomized rats as a model of post-menopausal osteoporosis, the administration of 
physiological doses of melatonin with adequate estrogen or pharmacological doses of 
melatonin is required to increase the bone mineral content or bone mineral density, 
respectively. 
Using the teleost scale assay system, physiological doses of melatonin were found to 
suppress both osteoclasts and osteoblasts. These findings are consistent with the results of in 
vivo studies in mammals. Thus, the scale assay system has utility in the development of new 
drugs for bone diseases, such as osteoporosis. 
A novel bromomelatonin derivative, 1-benzyl-2,4,6-tribromomelatonin, increases bone 
strength in ovariectomized rats and increases bone mineral density in rats fed a low-calcium 
diet. This melatonin derivative may have potential for use as a beneficial drug for bone 
diseases, such as osteoporosis. 
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Figure Legends 
 
Fig. 1. Diagram of a transverse section of teleost skin with scales (A), typical 
multi-nucleated osteoclasts (TRAP staining) (B) and osteoblasts (ALP staining) (C) in 
goldfish scales. Each arrowhead indicates multi-nucleated osteoclasts and osteoblasts.  
 

























































melatonin 2-bromomelatonin 2,4,6-tribromomelatonin 1-allyl-2,4,6-tribromo-
melatonin 
1-propargyl-2,4,6-tribromomelatonin 1-benzyl-2,4,6-tribromomelatonin 2,4,6,7-tetrabromomelatonin 
Table 1 Analysis of bone mineral density and stress-strain index in femoral metaphysis and 
diaphysis of ovariectomized (OVX) rats
SHAM                       5 672.3 ± 21.3          733.5± 12.5  280.9 ± 12.8            1278.0± 5.1                     6.34± 0.30
Bone mineral density (mg/cm3)                                         Stress-strain index
Metaphysis Diaphysis
N             Total    Subcortical + Cortical Trabecular Cortical           
OVX                         8         501.5 ± 11.9 680.8± 10.7        204.4 ± 6.9 1273.7 ± 4.9   6.60± 0.11
OVX + Br-MEL        6        519.3 ± 14.3 672.7± 23.0        212.6 ± 14.5 1274.0 ± 6.1 7.15± 0.18 *
Data as mean ± SE
*: significantly different (P<0.05)  from OVX rats and OVX + bromomelatonin (Br-MEL)-treated rats.
Table 2 Analysis of bone mineral density and stress-strain index in femoral metaphysis and 
diaphysis of rats fed a low-calcium diet 
Control                        6 330.5 ± 8.0           614.2 ± 16.6         160.4 ± 4.7             1219.9 ± 7.8                           5.33 ±0.17
Low dose Br-MEL      7 375.1 ± 7.6**       613.8 ± 13.9     179.5 ± 8.2             1224.0 ± 11.3                         5.58 ± 0.22
(0.3 mg/ animal)
High dose Br-MEL      6 364.6 ± 11.1*        645.3 ± 21.4         179.3 ± 11.9            1224.1 ± 7.6                           5.49 ± 0.36
(3 mg/ animal)
Data as mean ± SE
* and **: significantly different (P<0.05 and P<0.01, respectively) from control rats and bromomelatonin (Br-MEL)-treated 
rats.
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